Projects

Principal scientist
PharmDr. Katarína Bauerová, PhD., DrSc.

International

Finished
  • Application of bionic hydrogel enriched with selected natural compounds for repair of articular cartilage lesion.
    Program: Bilateral - other
    Duration: 1. 2. 2022 – 31. 12. 2023
  • Anti-inflammatory effects of natural compounds isolated from Vietnam medicinal plants
    Program: Bilateral - other
    Duration: 1. 4. 2020 – 30. 6. 2023
  • Collaboration on a complex pharmacological assessment of inflammatory diseases of the musculo-skeletal system and gastrointestinal tract on experimental animal models
    Program: Bilateral - other
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Anti-inflammatory effect of astaxanthin, sulforaphane and Crocus sativus extract evaluated in two rodent models of age related diseases.
    Program: Inter-academic agreement
    Duration: 1. 1. 2018 – 30. 6. 2021
  • Evaluation of Quercetin and Green Tea in combination with Methotrexate for arthritis therapy (Acronym: PhytoArt 2.0)
    Program: Bilateral - other
    Duration: 1. 1. 2016 – 31. 12. 2017
  • -
    Program: Bilateral - other
    Duration: 1. 1. 2013 – 31. 12. 2015
  • Role of the systemic inflammatory processes in the development of oxidative stress in the brain of arthritic subjects. Evaluation of experimental therapy based on new carnosine preparations
    Program: Bilateral - other
    Duration: 1. 1. 2013 – 31. 12. 2015
  • In vitro and in vivo models of arthritic processes for studying the mechanisms of inflammation and oxidative stress link-up. New perspectives for arthritis therapy
    Program: Bilateral - other
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Regulation of cytokine synthesis during inflammation develoment in brain and other tissues
    Program: Bilateral - other
    Duration: 1. 1. 2010 – 31. 12. 2012

National

Current
  • Preparation and quality control of modern dosage forms for alternative administration rout of biologics by inhalation (APVV-23-0508)
    Program: SRDA
    Duration: 1. 7. 2024 – 30. 6. 2028
  • Therapeutic intervention with bioactive compounds from bee products in experimental arthritis: evaluation of both articular and extra-articular complications
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
  • Pharmacological intervention in the treatment of cachexia by administering natural extracts (Crocus sativus and Ginkgo biloba) and substances (melittin, saffron, crocin, kaempferol and isorhamnetin) in combination with methotrexate and dexamethasone in an
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
  • The contribution of new nano-carrier drug delivery systems to the enhancement of the anti-inflammatory effect of D-limonene, phellandrene, isoborneol and chrysophanol studied in vivo (2/0091/23)
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
Finished
  • -
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • -
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2021
  • -
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • -
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Study of combination of immunosuppressive treatment and substances affecting redox balance of organism on animal models of rheumatoid arthritis
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • Cellular and molecular aspects of pharmacological regulation of neutrophil pro-inflammatory activity
    Program: SRDA
    Duration: 9. 9. 2008 – 30. 6. 2011
  • -
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • New pharmacological approaches affecting rheumatoid arthritis studied on adjuvant arthritis
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Molecular mechanisms of new drugs influencing oxidative stress - important ethiopathogenetic factor of numerous diseases
    Program: SRDA
    Duration: 1. 9. 2006 – 31. 10. 2009
  • Effect of immunostimulators and their combination with methotrexate on adjuvant arthrithis in rats
    Program: SRDA
    Duration: 1. 5. 2006 – 30. 4. 2009
  • Specific antagonists myocardial production and secretion of p roinflammatory cytokines(IC), expression of mitogenic vasopressor peptides (MP), polyferation and pathological remodelation after myocardial infarction (MI) and in chroni heart failure (CHF)
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
  • Effects of antioxidants and substances afecting the imunita systém studied in vivo using a model of adjuvant arthritis
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees